Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Core Scientific (CORZ) EBT (2020 - 2026)

Core Scientific has reported EBT over the past 7 years, most recently at -$346.6 million for Q1 2026.

  • Quarterly results put EBT at -$346.6 million for Q1 2026, down 160.12% from a year ago — trailing twelve months through Mar 2026 was -$1.2 billion (down 13.03% YoY), and the annual figure for FY2025 was -$288.0 million, up 79.96%.
  • EBT reached -$346.6 million in Q1 2026 per CORZ's latest filing, down from $216.1 million in the prior quarter.
  • Across five years, EBT topped out at $576.5 million in Q1 2025 and bottomed at -$936.6 million in Q2 2025.
  • Median EBT over the past 5 years was -$290.8 million (2024), compared with a mean of -$263.6 million.
  • The largest annual shift saw EBT tumbled 25965.69% in 2022 before it soared 74359.51% in 2024.
  • Over 5 years, EBT stood at -$456.3 million in 2022, then skyrocketed by 57.19% to -$195.4 million in 2023, then crashed by 48.84% to -$290.8 million in 2024, then skyrocketed by 174.3% to $216.1 million in 2025, then tumbled by 260.42% to -$346.6 million in 2026.
  • Business Quant data shows EBT for CORZ at -$346.6 million in Q1 2026, $216.1 million in Q4 2025, and -$143.9 million in Q3 2025.